Top

Clinical and Translational Oncology

Published in:

01-12-2017 | Research Article

Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia

Authors: Z. Wu, R. Chen, L. Wu, L. Zou, F. Ding, M. Wang, X. Liu

Published in: Clinical and Translational Oncology | Issue 12/2017

Abstract

Purpose

As a desmoplastic reaction, tissue fibrosis played crucial roles in solid tumor progression, chemo-resistance, and consequently heralded poor clinical outcome. Previous studies implied the effects of marrow fibrosis on prognosis for acute lymphoblastic leukemia were disputable. In this study, we aimed to investigate the potential role of bone marrow fibrosis on clinical survival in acute myeloid leukemia (AML) patients.

Methods

Bone marrow fibrosis (evaluated as reticulin fiber density, RFD) in bone marrow sections was evaluated at diagnosis via computer technology. Receiver operating characteristic curve (ROC) was used to analyze the predictive value of RFD for relapse and survival status. Kaplan–Meier method was used to estimate survival rates per subgroup between patients with different RFD. Cox proportional hazard regression was used to model the overall survival.

Results

High RFD at diagnosis in bone marrow sections from primary AML might predict early relapse and shorter survival (P = 0.003 and 0.001, respectively). The optimal cutoff value of RFD at diagnosis was determined to be 7.2%. Furthermore, the Kaplan–Meier analysis indicated that patients with high marrow RFD had shorter relapse-free survival (RFS) and overall survival (OS) than patients with low RFD (P = 0.007 and 0.000, respectively). Multivariate analysis suggested that similar with cytogenetics, marrow RFD at diagnosis was an independent prognostic factor for RFS [HR 0.564, 95% confidence interval (CI) 0.338–0.940, P = 0.028] and OS (HR 0.457, 95% CI 0.225–0.929, P = 0.031) in primary AML patients.

Conclusions

Our data suggest that marrow RFD before treatment should be seemed as prognostic factor in primary AML, it may provide valuable clues for developing new targeted therapy.

Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, Roberts MS, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013;122(22):3607–15. doi:10.1182/blood-2013-07-513044.CrossRefPubMedPubMedCentral

Ferreira PA, Ruela-de-Sousa RR, Queiroz KC, Souza AC, Milani R, Pilli RA, et al. Knocking down low molecular weight protein tyrosine phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl proteins. PLoS One. 2012;7(9):e44312. doi:10.1371/journal.pone.0044312.CrossRefPubMedPubMedCentral

Tabe Y, Konopleva M. Advances in understanding the leukaemia microenvironment. Br J Haematol. 2014;164(6):767–78. doi:10.1111/bjh.12725.CrossRefPubMedPubMedCentral

Yu Y, Wu Z, Zhang J, Zhai Y, Yuan Y, Liu S, et al. Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remission. J Transl Med. 2014;12:18. doi:10.1186/1479-5876-12-18.CrossRefPubMedPubMedCentral

Wu Z, Yu Y, Zhang J, Zhai Y, Tao Y, Shi J. Clustered immature myeloid precursors in intertrabecular region during remission evolve from leukemia stem cell near endosteum and contribute to disease relapse in acute myeloid leukemia. Med Hypotheses. 2013;80(5):624–8. doi:10.1016/j.mehy.2013.02.005.CrossRefPubMed

Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315–21.CrossRefPubMed

Al-Rakan MA, Colak D, Hendrayani SF, Al-Bakheet A, Al-Mohanna FH, Kaya N, et al. Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic. J Pathol. 2013;231(4):457–65. doi:10.1002/path.4256.CrossRefPubMedPubMedCentral

Wu X, Chen X, Zhou Q, Li P, Yu B, Li J, et al. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 2013;335(1):128–35. doi:10.1016/j.canlet.2013.02.002.CrossRefPubMed

Ueno H, Konishi T, Ishikawa Y, Shimazaki H, Ueno M, Aosasa S, et al. Histologic categorization of fibrotic cancer stroma in the primary tumor is an independent prognostic index in resectable colorectal liver metastasis. Am J Surg Pathol. 2014;38(10):1380–6. doi:10.1097/PAS.0000000000000232.CrossRefPubMed

10.

Buesche G, Georgii A, Duensing A, Schmeil A, Schlue J, Kreipe HH. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol. 2003;34(4):391–401.CrossRefPubMed

11.

Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol. 2001;19(12):2994–3009.CrossRefPubMed

12.

Eliacik E, Isik A, Aydin C, Uner A, Aksu S, Sayinalp N, et al. Bone marrow fibrosis may be an effective independent predictor of the ‘TKI drug response level’ in chronic myeloid leukemia. Hematology. 2015;20(7):392–6. doi:10.1179/1607845414Y.0000000221.CrossRefPubMed

13.

Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27(5):754–62. doi:10.1200/JCO.2008.18.2246.CrossRefPubMed

14.

Norén-Nyström U, Roos G, Bergh A, Forestier E. Prognostic impact of vascular density and fibrosis in the bone marrow of children with high-risk acute lymphoblastic leukemia. Leukemia. 2005;19(11):1998–2001.CrossRefPubMed

15.

Norén-Nyström U, Roos G, Bergh A, Botling J, Lönnerholm G, Porwit A, et al. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome. Leukemia. 2008;22(3):504–10.CrossRefPubMed

16.

Bharos A, Jong AJ, Manton N, Venn N, Story C, Hodge G, et al. Bone marrow fibrosis and vascular density lack prognostic significance in childhood acute lymphoblastic leukaemia. Leukemia. 2010;24(8):1537–8. doi:10.1038/leu.2010.134.CrossRefPubMed

17.

Thomas X, Le QH, Danaïla C, Lhéritier V, Ffrench M. Bone marrow biopsy in adult acute lymphoblastic leukemia: morphological characteristics and contribution to the study of prognostic factors. Leuk Res. 2002;26(10):909–18.CrossRefPubMed

18.

Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–9.CrossRefPubMed

19.

Yohe S. Molecular genetic markers in acute myeloid leukemia. J Clin Med. 2015;4(3):460–78. doi:10.3390/jcm4030460 (Review).CrossRefPubMedPubMedCentral

20.

Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemo-resistant niche. Cell. 2010;143(3):355–66. doi:10.1016/j.cell.2010.09.043.CrossRefPubMedPubMedCentral

21.

Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A, et al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. Leukemia. 2014;28(4):904–16. doi:10.1038/leu.2013.254.CrossRefPubMed

22.

Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008;6:11. doi:10.1186/1741-7015-6-11.CrossRefPubMedPubMedCentral

23.

Itano N, Zhuo L, Kimata K. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci. 2008;99(9):1720–5. doi:10.1111/j.1349-7006.2008.00885.x.CrossRefPubMed

24.

Wäster P, Rosdahl I, Gilmore BF, Seifert O. Ultraviolet exposure of melanoma cells induces fibroblast activation protein-α in fibroblasts: implications for melanoma invasion. Int J Oncol. 2011;39(1):193–202. doi:10.3892/ijo.2011.1002.PubMed

25.

Yamaguchi H, Yoshida N, Takanashi M, Ito Y, Fukami K, Yanagihara K, et al. Stromal fibroblasts mediate extracellular matrix remodeling and invasion of scirrhous gastric carcinoma cells. PLoS One. 2014;9(1):e85485. doi:10.1371/journal.pone.0085485 (eCollection 2014).CrossRefPubMedPubMedCentral

26.

Hanley CJ, Noble F, Ward M, Bullock M, Drifka C, Mellone M, et al. A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. Oncotarget. 2016;7(5):6159–74. doi:10.18632/oncotarget.6740.CrossRefPubMed

27.

Nakayama S, Yokote T, Hiraoka N, Akioka T, Nishiwaki U, Miyoshi T, et al. Transforming growth factor β- and interleukin 13-producing mast cells are associated with fibrosis in bone marrow. Hum Pathol. 2017;62:180–6. doi:10.1016/j.humpath.2017.01.007.CrossRefPubMed

28.

Nath SV, Nicholson I, Tapp H, Zola H, Zannettino AC, Revesz T. Reticulin fibres anchor leukaemic blasts in the marrow of patients with acute lymphoblastic leukaemia. Med Hypotheses. 2011;77(3):333–5. doi:10.1016/j.mehy.2011.05.007.CrossRefPubMed

29.

Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27(18):2991–9. doi:10.1200/JCO.2008.20.3174.CrossRefPubMedPubMedCentral

30.

Troeger A, Johnson AJ, Wood J, Blum WG, Andritsos LA, Byrd JC, et al. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. Blood. 2012;119(20):4708–18. doi:10.1182/blood-2011-12-395939.CrossRefPubMedPubMedCentral

31.

Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, Scielzo C, et al. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood. 2016;127(16):1987–97. doi:10.1182/blood-2015-07-657056.CrossRefPubMedPubMedCentral

32.

Shi JL, Fu L, Ang Q, Wang GJ, Zhu J, Wang WD. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget. 2016;7(3):2585–95. doi:10.18632/oncotarget.6226.CrossRefPubMed

33.

Falk IJ, Willander K, Chaireti R, Lund J, Nahi H, Hermanson M, et al. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome. Eur J Haematol. 2015;94(4):355–62. doi:10.1111/ejh.12438.CrossRefPubMed

34.

Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T, et al. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leuk Res. 2013;37(9):1021–6. doi:10.1016/j.leukres.2013.05.002.CrossRefPubMed

35.

Xu S, Li X, Zhang J, Chen J. Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis. J Cancer Res Clin Oncol. 2015;141(10):1859–70. doi:10.1007/s00432-015-1977-3.CrossRefPubMed

Title: Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia
Authors: Z. Wu
R. Chen
L. Wu
L. Zou
F. Ding
M. Wang
X. Liu
Publication date: 01-12-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 12/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1687-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2017

Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells

Pancreatic ductal adenocarcinoma: metastatic disease

Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

Overexpression of dishevelled 2 is involved in tumor metastasis and is associated with poor prognosis in hepatocellular carcinoma

Biomarkers in pancreatic ductal adenocarcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer